^
Association details:
| Biomarker: | HLA-A*02:01 |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | BSB-1001 (TCR modulator, Minor histocompatibility antigen 1 modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
275 Manufacture of allogeneic, HLA-matched, TCR-edited T-cell therapy reactive against minor histocompatibility antigen 1 to treat acute myeloid leukemia in combination with CD34 HSCT with the potential for high potency and durability
Published date:
11/08/2022
Excerpt:
BSB-1001 cells showed efficient killing of HA-1+ LCL222 cells, but not HA-1 -/- LCL224 cells....Taken together, the results indicate that BSB-1001 is an active, highly potent drug product candidate, with a potential to be effective in treating HA-1+ HLA-A*02:01 AML patients…
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0275
